Zoetis Inc. (NYSE:ZTS) Shares Bought by Lebenthal Global Advisors LLC

Lebenthal Global Advisors LLC boosted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 9.2% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 1,266 shares of the company’s stock after purchasing an additional 107 shares during the quarter. Lebenthal Global Advisors LLC’s holdings in Zoetis were worth $247,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Hills Bank & Trust Co increased its holdings in shares of Zoetis by 13.5% in the 3rd quarter. Hills Bank & Trust Co now owns 2,082 shares of the company’s stock valued at $407,000 after purchasing an additional 247 shares during the period. US Bancorp DE grew its holdings in Zoetis by 0.4% during the third quarter. US Bancorp DE now owns 151,819 shares of the company’s stock valued at $29,665,000 after purchasing an additional 637 shares during the last quarter. Congress Asset Management Co. grew its holdings in Zoetis by 0.4% during the third quarter. Congress Asset Management Co. now owns 689,804 shares of the company’s stock valued at $134,774,000 after purchasing an additional 3,072 shares during the last quarter. Catalyst Financial Partners LLC grew its holdings in Zoetis by 3.6% during the third quarter. Catalyst Financial Partners LLC now owns 2,247 shares of the company’s stock valued at $439,000 after purchasing an additional 78 shares during the last quarter. Finally, Financial Advocates Investment Management grew its stake in shares of Zoetis by 6.2% in the third quarter. Financial Advocates Investment Management now owns 3,451 shares of the company’s stock worth $674,000 after acquiring an additional 200 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of Zoetis stock opened at $181.95 on Friday. The firm has a market capitalization of $82.43 billion, a P/E ratio of 35.61, a price-to-earnings-growth ratio of 2.78 and a beta of 0.90. The business’s fifty day simple moving average is $188.97 and its 200 day simple moving average is $178.51. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $201.92.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.49 by $0.07. The firm had revenue of $2.36 billion for the quarter, compared to analyst estimates of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The business’s revenue was up 8.3% on a year-over-year basis. During the same period in the previous year, the company posted $1.41 earnings per share. As a group, analysts anticipate that Zoetis Inc. will post 5.83 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be given a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a yield of 0.95%. The ex-dividend date is Thursday, October 31st. Zoetis’s payout ratio is 33.66%.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Piper Sandler lifted their price target on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Argus raised Zoetis to a “strong-buy” rating in a report on Friday, August 9th. JPMorgan Chase & Co. lifted their price objective on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. BTIG Research boosted their target price on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Finally, Stifel Nicolaus boosted their price objective on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday, September 18th. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Zoetis presently has a consensus rating of “Buy” and an average price target of $221.44.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.